Illumina, Inc. Q2 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Life Sciences Tools and Services | Market Cap: ₹24.0K Cr
- Illumina expects continued strong momentum in clinical sales, projecting mid-teens growth for the clinical market, with potential upside beyond current guidance. - Illumina expects continued revenue growth with an updated 2026 revenue guidance raised to $4.52 billion to $4.62 billion, reflecting Q1 outperformance.
From Illumina, Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹158.7
Market Cap
₹24.0K Cr
P/E Ratio
26.4
Revenue Rank
Margin Rank
How does Illumina, Inc. rank in Life Sciences Tools and Services?
Compare Illumina, Inc. against every Life Sciences Tools and Services company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 3- →Illumina expects continued strong momentum in clinical sales, projecting mid-teens growth for the clinical market, with potential upside beyond current guidance.
- →Research and applied markets are expected to remain cautious, with mid- to high single-digit declines anticipated for the year, though some improvement is possible later in 2026.
- →NovaSeq X instrument placements remain strong, with demand outpacing supply; over 85% of clinical customer transition to NovaSeq X is expected by year-end 2026.
- →Total sequencing gigabase output grew over 30% year-over-year, driven mainly by clinical growth well above that.
- →Revenue guidance for 2026 was raised to $4.52 billion to $4.62 billion, with Rest of World organic growth expected at 2-4%, clinical consumables growth in low double digits to mid-teens, and research consumables down mid- to high single digits.
- →Instrument revenue is expected to be flat to low single-digit growth, driven by NovaSeq X demand.
- →Operational improvements and scale benefits are forecasting continued margin expansion alongside revenue growth.
📈 Profitability & Margins
Rank 1- →Illumina expects continued revenue growth with an updated 2026 revenue guidance raised to $4.52 billion to $4.62 billion, reflecting Q1 outperformance.
- →Operating margins are forecasted to expand by approximately 140 basis points year-over-year in 2026, targeting 23.4% to 23.6%, up 10 basis points from prior guidance.
- →Non-GAAP EPS guidance for 2026 is increased to a range of $5.15 to $5.30, representing about 12% growth at the midpoint excluding acquisitions.
- →They anticipate mid-single-digit organic growth in 2026 with a focus on mid-teens growth in the clinical market segment.
- →Operating margin improvements are expected despite short-term inflationary pressures, with mitigating actions to offset these effects fully.
- →Instrument placements and consumables growth, especially driven by NovaSeq X adoption, are key drivers of profitable growth.
- →Long-term targets include achieving high single-digit growth and approximately 500 basis points of margin expansion by 2027.
🏗️ Capital Expenditure Plans
Yes- →In Q1 2026, Illumina's capital expenditures were $38 million.
- →The company is scaling up BioInsight, which may involve strategic investments; timing of partnerships and data deals can be lumpy.
- →Operational focus includes investment to scale supply, noted as a headwind in Q2 with effects visible in Q3 and Q4.
- →Illumina closed the acquisition of SomaLogic on January 30, 2026, with a net cash payment of $363 million plus potential royalties and milestone payments.
- →Subsequent to quarter-end, Illumina paid the first milestone of $25 million related to SomaLogic's 2025 targets.
- →The board authorized an additional $1.5 billion in share repurchases, signaling capital allocation toward shareholder returns.
- →The company emphasizes strong operational discipline and mitigating inflationary pressures while investing in innovation and supply capabilities.
💰 Fundraising & Capital Structure
No information- →In Q1, Illumina repurchased 2 million shares for approximately $242 million, indicating active capital deployment.
- →At quarter end, approximately $400 million remained on the current share repurchase authorization.
- →The Board authorized an additional $1.5 billion in share repurchases, showing a commitment to returning capital to shareholders.
- →Illumina ended Q1 with approximately $1.16 billion in cash, cash equivalents, and short-term investments.
- →Gross leverage stood at approximately 1.5x gross debt to last 12 months EBITDA.
- →No mention was made of new fundraising through debt or equity during the quarter or upcoming periods.
- →The focus appears to be on share repurchases and managing existing financial resources rather than raising new funds.
📋 Order Book & Pipeline
Yes- →Illumina is experiencing very strong demand and a robust pipeline for both instruments and consumables.
- →Year-over-year, performance obligations (indicating backlog) are up more than 20%.
- →Supply constraints exist but the company is scaling up production to meet demand.
- →Q2 placements are expected to be close to Q1 levels (~80 NovaSeq X units).
- →The pipeline for the remainder of the year looks robust, indicating strong orderbook visibility.
- →Much of the demand is driven by new trials and tests, evidencing growth in both clinical and research sectors.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Life Sciences Tools and Services this season
- Revvity, Inc. (Q2 FY26)
Revvity, Inc. Q2 FY26 quarterly results analysis. 2026 revenue guidance updated to $2.81 billion - $2.84 billion, with pro forma organic growth expected at 3% t
- Medpace Holdings, Inc. (Q2 FY26)
Medpace Holdings, Inc. Q2 FY26 quarterly results analysis. Revenue is expected to remain within the current guidance range for 2026 despite higher cancellations
- Mettler-Toledo International Inc. (Q2 FY26)
Mettler-Toledo International Inc. Q2 FY26 quarterly results analysis. The company expects local currency sales growth of approximately 4% for full year 2026, in
- West Pharmaceutical Services, Inc. (Q2 FY26)
West Pharmaceutical Services, Inc. Q2 FY26 quarterly results analysis. Revenue growth guidance for 2026 increased to 7% to 9% organic growth, reflecting strong
Frequently Asked Questions
What were Illumina, Inc. Q2 FY26 results?
- Illumina expects continued strong momentum in clinical sales, projecting mid-teens growth for the clinical market, with potential upside beyond current guidance. - Illumina expects continued revenue growth with an updated 2026 revenue guidance raised to $4.52 billion to $4.62 billion, reflecting Q1 outperformance.
What is Illumina, Inc. share price analysis?
Illumina, Inc. currently shows a below-average growth signal. The stock trades at a P/E of 26.4 with a market cap of $24,011. Investors should review the full earnings analysis for detailed insights.
Is Illumina, Inc. planning capital expenditure?
- In Q1 2026, Illumina's capital expenditures were $38 million.
Keep Illumina, Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.